# Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

> **NCT02006485** · PHASE1 · COMPLETED · sponsor: **TG Therapeutics, Inc.** · enrollment: 160 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Ublituximab + TGR-1202
- **DRUG:** Ublituximab + TGR-1202 + ibrutinib
- **DRUG:** Ublituximab + TGR-1202 + bendamustine

## Key facts

- **NCT ID:** NCT02006485
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-13
- **Primary completion:** 2019-10
- **Final completion:** 2019-10
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2019-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02006485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02006485, "Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02006485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*